| Literature DB >> 31771586 |
Qi Han1,2, Xueyang Li3, Qiushi Tan4, Jing Shao4, Muqing Yi4,5.
Abstract
BACKGROUND: The purpose of this systematic review and meta-analysis is to investigate the effects of vitamin D3 supplementation on skeletal muscle strength in athletes. Vitamin D3 supplements or vitamin D3 fortified foods always have claims for bringing people health benefits including bone and muscle health. An up-to-date rigorous systematic review and meta-analysis is important to better understand the effect of vitamin D3 supplementation on muscle strength.Entities:
Keywords: 25(OH)D; Exercise; Muscle; Physical fitness; Strength and conditioning
Mesh:
Substances:
Year: 2019 PMID: 31771586 PMCID: PMC6878631 DOI: 10.1186/s12970-019-0323-6
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Fig. 1PRISMA flow diagram of search and selection process
Fig. 2Funnel plot for within study serum 25(OH)D difference between intervention and placebo for each trial at baseline. SE, standard error; MD, mean difference of serum 25(OH)D between intervention and placebo. Close 2013a included 2 different vitamin D3 dosage intervention groups in their study [28]
Fig. 3Cochrane risk of bias assessment. 2013a, 30 football and rugby athletes were recruited in reference 28; 2013b, 10 soccer players were recruited in reference 32
Characteristics of the included randomized controlled trials
| Reference | Country | Latitude | Season | Sports Activity | Randomized ( | Intervention Vitamin D Dosage IU (μg) | Duration | Type | Product |
|---|---|---|---|---|---|---|---|---|---|
| Jung 2018 [ | Korea | 33.3° N | Winter | Taekwondo | 22/22 | 5000 | 4 weeks | D3 capsules | Bio-Tech Pharmacal, Inc. (Arkansas, USA) |
| Fairbairn 2018 [ | New Zealand | 45–46.5° S | Autumn | Rugby | 28/29 | 3570 IU (89 μg)/day | 11–12 weeks | D3 tablets | Cal.D.Forte, PSM Healthcare, Auckland, New Zealand |
| Close 2013b [ | UK | 53° N | Winter | Soccer | 5/5 | 5000(125)/day vs. PL | 8 weeks | D3 capsules | Biotech Pharmacal Inc., Phoenix, AZ, USA |
| Close 2013a [ | UK | 53° N | Winter | Football and Rugby | 10/10/10 | 20,000 (500)/week vs. 40,000 (1000)/week vs. PL | 12 weeks | D3 capsules | Biotech Pharmacal Inc., Phoenix, AZ, USA |
| Wyon 2016 [ | UK | 52.3° N | Winter | Judo | 11/11 | 150,000 (3750)/one time vs. PL | 8 days | D3 tablets | Not reported |
Data are means unless stated otherwise; PL Placebo. 2013a, 30 football and rugby athletes were recruited in reference 28; 2013b, 10 soccer players were recruited in reference [32]
Baseline measurements of the included randomized controlled trials
| Reference | Analyzed ( | VD3 Daily Dosage IU | Males (%) | Mean Age Years | 25(OH)D (ng/mL) | 25(OH)D (nmol/L) | 25(OH)D Method of Analysis | Lost to Follow-up |
|---|---|---|---|---|---|---|---|---|
| Jung 2018 [ | 20 | 5000 | 60% (21/35) | 20.1 ± 0.15 | 10.9 ± 0.47 | 27.3 ± 1.18 | CLIA analyzer (Liaison XL, Dasorin, Italy) | 9 |
| 15 | PL | 12.36 ± 0.78 | 30.9 ± 1.95 | (20.45%) | ||||
| Fairbairn 2018 [ | 28 | 3570 | 100 | 21.5 ± 2.8 | 37.2 ± 7.6 | 93 ± 19 | LC-MS/MS at Canterbury Health Laboratories, Christchurch, New Zealand | 0 |
| 29 | PL | 20.9 ± 2.8 | 38 ± 6.8 | 95 ± 17 | ||||
| Close 2013b [ | 5 | 5000 | 100 | 18 ± 5 | 11.6 ± 10 | 29 ± 25 | HPLC-MRM (Becton Dickinson, Oxford, UK) | 0 |
| 5 | PL | 21.2 ± 11.6 | 53 ± 29 | |||||
| Close 2013a [ | 6 | 5714 | 100 | 21 ± 1 | 20.4 ± 10.4 | 51 ± 26 | HPLC-MRM (Becton Dickinson, Oxford, UK) | 5 |
| 10 | 2857 | 22 ± 2 | 21.2 ± 10.4 | 53 ± 26 | (16.70%) | |||
| 9 | PL | 21 ± 1 | 20.8 ± 10.8 | 52 ± 27 | ||||
| Wyon 2016 [ | 11 | 18,750 | 100 | 29 ± 10.6 | 13.2 ± 3.8 | 32.8 ± 9.4 | ECLIA (Tecan Infinite F500, Mannedorf, Switzerland) | 0 |
| 11 | PL | 26 ± 7.4 | 16.3 ± 2.7 | 40.7 ± 6.8 |
Data are mean ± standard deviation unless stated otherwise. CLIA Chemiluminescent immunoassay, ECLIA Electrochemiluminescent immunoassay, HPLC-MRM High-performance liquid chromatography tandem multiple reaction mode, HPLC-MS High-performance liquid chromatography-tandem mass spectrometry, LC–MS/MS Liquid chromatography mass spectrometry, PL Placebo. 2013a, 30 football and rugby athletes were recruited in reference 28; 2013b, 10 soccer players were recruited in reference [32]
Baseline and Follow-up Serum 25(OH)D concentrations
| Reference | Latitude | Time | Vitamin D3 Daily Dosage | Baseline (ng/mL) | 1 Week (ng/mL) | 4 Weeks (ng/mL) | 6 Weeks (ng/mL) | 8 Weeks (ng/mL) | 12 Weeks (ng/mL) | |
|---|---|---|---|---|---|---|---|---|---|---|
| IU | ||||||||||
| Jung 2018 [ | 33.3° N | Jan–Feb | 5000 | 10.9 ± 0.5 | 20 | 38.4 ± 1.5 | ||||
| 0 | 12.4 ± 0.8 | 15 | 13.1 ± 1.0 | |||||||
| Fairbairn 2018 [ | 45–46.5° S | Mar–May | 3570 | 37.2 ± 7.6 | 28 | 44.4 ± 7.2 | 45.6 ± 7.6 | |||
| 0 | 38 ± 6.8 | 29 | 34 ± 6.8 | 32 ± 8.4 | ||||||
| Close 2013b [ | 53° N | Nov–Jan | 5000 | 11.6 ± 10.0 | 5 | 41.3 ± 10.0 | ||||
| 0 | 21.2 ± 11.6 | 5 | 29.6 ± 9.6 | |||||||
| Close 2013a [ | 53° N | Jan–Apr | 5714 | 20.4 ± 10.4 | 6 | 39.3 ± 5.6 | 36.5 ± 9.6 | |||
| 2857 | 21.2 ± 10.4 | 10 | 31.7 ± 5.6 | 34.1 ± 4.0 | ||||||
| 0 | 20.8 ± 10.8 | 9 | 14.8 ± 7.2 | 16.4 ± 8.8 | ||||||
| Wyon 2016 [ | 52.3° N | Feb | 18,750 | 13.2 ± 3.8 | 11 | 16.8 ± 3.2 | ||||
| 0 | 16.3 ± 2.7 | 11 | 16.3 ± 2.6 |
Data are mean ± standard deviation unless stated otherwise. Measurements are in ng/mL
Baseline and end-point mean 25(OH)D concentrations in vitamin D and placebo
| Reference | Latitude | Vitamin D Daily Dosage (IU) | Weeks | Vitamin D Supplementationa | Placeboa | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Pre | Post | Change | N | Pre | Post | Change | ||||
| Insufficient vitamin D ( | |||||||||||
| Winter ( | |||||||||||
| Jung 2018 [ | < 45° N | 5000 | 4 | 20 | 10.9 ± 0.5 | 38.4 ± 1.5 | 17.5 | 15 | 12.4 ± 0.8 | 13.1 ± 1.0 | 0.7 |
| Close 2013b [ | ≥45° N | 5000 | 6 | 5 | 11.6 ± 10.0 | 41.3 ± 10.0 | 29.7 | 5 | 21.2 ± 11.6 | 29.6 ± 9.6 | 8.4 |
| bClose 2013a [ | ≥45° N | 5714 | 12 | 6 | 20.4 ± 10.4 | 36.5 ± 9.6 | 16.1 | 9^ | 20.8 ± 10.8 | 16.4 ± 8.8 | −4.4 |
| bClose 2013a [ | ≥45° N | 2857 | 12 | 10 | 21.2 ± 10.4 | 34.1 ± 4.0 | 12.9 | 9^ | 20.8 ± 10.8 | 16.4 ± 8.8 | − 4.4 |
| Wyon 2016 [ | ≥45° N | 18,750 | 1 | 11 | 13.2 ± 3.8 | 16.8 ± 3.2 | 3.6 | 11 | 16.3 ± 2.7 | 16.3 ± 2.6 | 0 |
| Sufficient vitamin D ( | |||||||||||
| Autumn ( | |||||||||||
| Fairbairn 2018 [ | ≥45° S | 3570 | 12 | 28 | 37.2 ± 7.6 | 44.4 ± 7.2 | 7.2 | 29 | 38 ± 6.8 | 34 ± 6.8 | −4 |
aPresented in ng/mL. bClose et al. compared multiple doses with one control group. ^ Indicates findings are from one study
Fig. 4Forest plot for vitamin D3 supplementation effects on serum 25(OH)D status
Fig. 5Sensitivity analysis for vitamin D3 supplementation effects on serum 25(OH)D status
Strength outcome measures
| Reference | Vitamin D Daily Dosage | 1-RM BP (kg) | Quadriceps Contr. (N·m) | |||||
|---|---|---|---|---|---|---|---|---|
| IU | Pre | Post | Change | Pre | Post | Change | ||
| aJung 2018 [ | 5000 | 20 | 323.6 ± 7.3 | 350.4 ± 7.5 | 25.8 | |||
| 0 | 15 | 329.9 ± 8.4 | 339.2 ± 8.7 | 9.3 | ||||
| Fairbairn 2018 [ | 3570 | 28 | 126 ± 17 | 122 ± 15 | −4 | |||
| 0 | 29 | 122 ± 17 | 123 ± 16 | 1 | ||||
| bClose 2013b [ | 5000 | 5 | 82 ± 14 | 88.5 ± 14 | 6.5 | |||
| 0 | 5 | 82 ± 14 | 84.5 ± 14 | 2.5 | ||||
| Close 2013a [ | 5714 | 6 | 91 ± 22 | 90 ± 20 | −1 | |||
| 2857 | 10 | 90 ± 13 | 92 ± 15 | 2 | ||||
| 0 | 9 | 79 ± 17 | 79 ± 18 | 0 | ||||
| cWyon 2016 [ | 18,750 | 11 | 232 ± 37.4 | 265 ± 45.6 | 33 | |||
| 0 | 11 | 239 ± 65.9 | 239 ± 63.7 | 0 | ||||
aDid 3 maximal quadriceps contraction at 60°/s; bBaseline measured from an average from 10 participants; cDid 3 maximal quadriceps contraction at 30°/s
Fig. 6Forest plot for vitamin D3 supplementation effects on muscle strength